Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNK-UT004
- Development stage
- Preclinical
- Lead developer
- ST Phi Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CNK-UT004 is an allogeneic T-cell therapy being developed by ST Phi Therapeutics for the treatment of various solid tumors, including neuroblastoma, renal carcinoma, melanoma, and lung cancer. The therapy utilizes the company's proprietary CNK-UT platform, where T cells are engineered with a chimeric natural killer (NK) receptor (CNK). This receptor is designed to recognize a broad range of NK cell receptor ligands that are frequently overexpressed on the surface of tumor cells, allowing the engineered T cells to target and eliminate cancer cells across multiple indications. As of early 2025, the program is in the IND-enabling stage, with an IND filing milestone projected for June 2025.
- Other names
- CNK-UT004CNK-UT-004CNK-UT 004
02
Targets
MICB (Major histocompatibility complex class i-related protein B)B7-H3
Beyond the preview
Go deeper on CNK-UT004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNK-UT004.